These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8794364)

  • 41. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings.
    Saeng-Aroon S; Wichukchinda N; Myint L; Pathipvanich P; Ariyoshi K; Rojanawiwat A; Matsuda M; Sawanpanyalert P; Sugiura W; Auwanit W
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1051-6. PubMed ID: 15247558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.
    Nakano T; Morozumi H; Inuzuka S; Nagata M; Taguchi Y; Mizokami M; Okamoto T
    AIDS Res Hum Retroviruses; 1997 May; 13(7):563-73. PubMed ID: 9135874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
    Schneider A; Corona A; Spöring I; Jordan M; Buchholz B; Maccioni E; Di Santo R; Bodem J; Tramontano E; Wöhrl BM
    Nucleic Acids Res; 2016 Mar; 44(5):2310-22. PubMed ID: 26850643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.
    Brindeiro R; Vanderborght B; Caride E; Correa L; Oravec RM; Berro O; Stuyver L; Tanuri A
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1674-80. PubMed ID: 10390221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
    Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
    Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
    Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
    J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
    Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
    J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.
    Hostetler KY; Hammond JL; Kini GD; Hostetler SE; Beadle JR; Aldern KA; Chou TC; Richman DD; Mellors JW
    Antivir Chem Chemother; 2000 May; 11(3):213-9. PubMed ID: 10901292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.
    Yahi N; Tamalet C; Tourrès C; Tivoli N; Fantini J
    J Biomed Sci; 2000; 7(6):507-13. PubMed ID: 11060499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
    Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
    Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA; Kemp SD
    Science; 1989 Dec; 246(4934):1155-8. PubMed ID: 2479983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
    Sheehy N; Desselberger U
    J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy.
    Smith MS; Koerber KL; Pagano JS
    Leukemia; 1994 Apr; 8 Suppl 1():S179-82. PubMed ID: 8152287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.